단일 세포 분석 시장 : 시장 기회, 성장 촉진요인, 산업 동향 분석, 예측(2025-2034년)

The Global Single-cell Analysis Market was valued at USD 4.3 billion in 2024 and is estimated to grow at a CAGR of 16.7% to reach USD 20 billion by 2034.

The strong growth is driven by increasing interest in personalized medicine and continued advances in transcriptomics and genomics technologies. Single-cell analysis allows scientists to examine the unique behavior of individual cells within complex populations, offering a deeper understanding of disease progression, drug resistance, immune responses, and metastasis. The technology plays a vital role in detecting rare cancer cells, assessing treatment responses, and uncovering cellular heterogeneity. Unlike conventional bulk analysis, single-cell techniques deliver high-resolution data that is crucial for studying tumor evolution, rare genetic disorders, and cellular development. Due to the low volume and sensitivity of samples, these methods rely on highly precise protocols. The integration of multi-omics covering transcriptomics, epigenomics, proteomics, and metabolomics at the single-cell level helps deliver a comprehensive picture of cell function. Additionally, advancements in 3D spatial omics technologies allow researchers to explore cellular interactions and environmental cues in their native tissue context, unlocking deeper insights into biological systems and advancing applications in diagnostics, drug discovery, and regenerative medicine.

The consumables segment held a 56.3% share in 2024 and is forecasted to reach USD 11.4 billion by 2034, growing at a CAGR of 16.9%. This segment includes reagents, beads, assay kits, and microfluidic cartridges that are critical for single-cell workflows. As these products are consumed in every experiment and must be replenished regularly, they create ongoing demand. The increasing frequency of studies in fields like stem cell biology, immunotherapy, and oncology is fueling the need for consumables, especially as researchers scale up experiments in academic and commercial settings.

The genomics (DNA) application segment generated USD 1.8 billion in 2024. Single-cell genomics provides a powerful way to detect genetic differences between individual cells, offering insight into chromosomal variations, mutations, and clonal evolution. This technology is instrumental in studying disease mechanisms at a granular level, identifying residual disease, and uncovering rare genetic variants that may be overlooked in bulk DNA analysis. It is especially valuable in tracking tumor subpopulations and understanding the genetic makeup of complex tissues.

North America Single-cell Analysis Market held a 45.1% share in 2024. The region's leadership stems from strong investments in R&D, particularly in the U.S., where the presence of major biotech and pharmaceutical companies supports continued innovation. High healthcare spending enables institutions to adopt sophisticated technologies, while academic research hubs and clinical trial networks actively support the growth of single-cell technologies across a wide range of therapeutic areas.

Key players in the Global Single-cell Analysis Market include Illumina, Takara Bio, 10X Genomics, Sartorius, Oxford Nanopore Technologies, Thermo Fisher Scientific, Merck KGaA, Agilent Technologies, BGI Genomics, Fluidigm Corporation (Standard Bio Tools), NanoString Technologies, Novogene, Bio-Rad Laboratories, QIAGEN NV, and Becton, Dickinson & Company (BD). To solidify their position in the Single-cell Analysis Market, leading companies are expanding their product lines to include multi-omics platforms that integrate genomic, proteomic, and spatial technologies. Many are forging partnerships with academic institutions and biopharma firms to support large-scale research projects. Investment in R&D remains a core focus, with continuous innovation in microfluidics, sequencing technologies, and automation tools. Firms are also increasing their global footprint by enhancing distribution networks and establishing new facilities to meet growing demand.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Data mining sources
  • 1.3.1 Global
  • 1.3.2 Regional/Country
• 1.4 Base estimates and calculations
  • 1.4.1 Base year calculation
  • 1.4.2 Key trends for market estimation
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
• 1.6 Forecast model
• 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
• 2.2 Key market trends
  • 2.2.1 Regional trends
  • 2.2.2 Component trends
  • 2.2.3 Application trends
  • 2.2.4 End use trends
• 2.3 CXO perspectives: Strategic imperatives
  • 2.3.1 Key decision points for industry executives
  • 2.3.2 Critical success factors for market players
• 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Growing demand for personalized medicine
    • 3.2.1.2 Advancement in genomics and transcriptomics technologies
    • 3.2.1.3 Growing applications in cancer research
    • 3.2.1.4 Increasing government and private funding
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of instruments and reagents
    • 3.2.2.2 Complex data analysis and interpretation
  • 3.2.3 Market opportunities
    • 3.2.3.1 Increasing expansion in clinical diagnostics
    • 3.2.3.2 Growth in biotech and pharma collaborations
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 North America
    • 3.4.1.1 U.S.
    • 3.4.1.2 Canada
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
  • 3.4.4 Latin America
  • 3.4.5 Middle East and Africa
• 3.5 Technology landscape
  • 3.5.1 Current technological trends
  • 3.5.2 Emerging technologies
• 3.6 Pipeline analysis
• 3.7 Pricing analysis
• 3.8 Future market trends
• 3.9 Porter's analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company market share analysis
  • 4.2.1 Global
  • 4.2.2 North America
  • 4.2.3 Europe
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Merger and acquisition
  • 4.6.2 Partnership and collaboration
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Consumables
  • 5.2.1 Reagents
  • 5.2.2 Assay Kits
• 5.3 Instruments
  • 5.3.1 Microscopes
  • 5.3.2 Hemocytometers
  • 5.3.3 Flow cytometers
  • 5.3.4 Next generation sequencing
  • 5.3.5 High-content screening system
  • 5.3.6 Other instruments

Chapter 6 Market Estimates and Forecast, By Analysis Type, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Genomics (DNA)
• 6.3 Transcriptomics
• 6.4 Epigenomics
• 6.5 Multiomics integration
• 6.6 Other analysis types

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Clinical diagnostics
• 7.3 Research
• 7.4 Drug discovery & development
• 7.5 Other applications

Chapter 8 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Academic and research laboratories
• 8.3 Biotechnology and pharmaceutical companies
• 8.4 Hospitals and diagnostic laboratories
• 8.5 Other end use

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 India
  • 9.4.3 Japan
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 10X Genomics
• 10.2 Agilent Technologies
• 10.3 Becton, Dickinson & Company (BD)
• 10.4 Bio-Rad Laboratories
• 10.5 BGI Genomics
• 10.6 Fluidigm Corporation (Standard Bio Tools)
• 10.7 Illumina
• 10.8 Merck KGaA
• 10.9 NanoString Technologies
• 10.10 Novogene
• 10.11 Oxford Nanopore Technologies
• 10.12 QIAGEN NV
• 10.13 Sartorius
• 10.14 Takara Bio
• 10.15 Thermo Fisher Scientific